VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | Anti-PD-L1/TGF-β trap in non-HPV associated HNSCC

VJOncology is committed to improving our service to you

Jason Redman

Jason Redman, MD, National Cancer Institute, Bethesda, MD, outlines the rationale behind a Phase I/II study evaluating M7824, a bifunctional immunotherapy consisting of a TGF‑β trap and anti-PD-L1, with or without TriAd vaccine and N-803, for p16-negative resectable head and neck squamous cell carcinoma (HNSCC) not associated with HPV infection. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter